Johnson & Johnson Q1 Earnings Top Wall Street Estimates On Strong Medical Devices Sales, Drugmaker Boosts Annual Outlook

Zinger Key Points
  • J&J's medical devices business generated sales of $7.82 billion during the first quarter, up 4.5% Y/Y.
  • Johnson & Johnson also raised its quarterly dividend by 4.2% from $1.19 per share to $1.24 per share.

On Tuesday, Johnson & Johnson JNJ reported first-quarter adjusted EPS of $2.71, up 12.4% year over year, beating the consensus of $2.64.

The pharma giant reported sales of $21.38 billion, up 2.3% year over year, almost in line with the consensus of $21.39 billion. Operational growth was 3.9%, and adjusted operational growth was 4.0%.

JNJ reported a net profit of $5.35 billion compared to a net loss of $(491) million a year ago, which included litigation charges of $6.9 billion.

Innovative Medicine segment worldwide operational sales, excluding the COVID-19 Vaccine, grew 8.3% to $13.6 billion.

Sales of its psoriasis drug Stelara were flat at $2.45 billion in the first quarter, while sales of Darzalex jumped about 19% to $2.69 billion.

The company’s cancer cell therapy Carvykti, which recently received expanded use FDA approval for patients with a type of blood cancer, brought in sales of $157 million in the first quarter.

Tecvayli, another blood cancer treatment, accounted for $133 million in quarterly sales.

J&J’s medical devices business generated sales of $7.82 billion during the first quarter, up 4.5% Y/Y, driven primarily by electrophysiology products and Abiomed in Cardiovascular and wound closure products in General Surgery.

Dividend: Johnson & Johnson also raised its quarterly dividend by 4.2% from $1.19 per share to $1.24 per share.

Guidance: Johnson & Johnson forecasts fiscal year 2024 operational sales of $88.7 billion-$89.1 billion versus prior guidance of $88.2 billion–$89.0 billion and consensus of $88.43 billion.

The company expects fiscal year 2024 adjusted EPS of $10.57–$10.72 versus consensus of $10.66 and prior guidance of $10.55–$10.75, with adjusted operational EPS of $10.60–$10.75.

Read Next: Johnson & Johnson’s $13B Shockwave Medical Deal Accelerates MedTech Strategy, Analyst Says.

Price Action: JNJ shares are down 1.69% at $145.10 during the premarket session on the last check Tuesday.

Photo via Wikimedia Commons

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareTop StoriesGeneralBriefsStories That Matter
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!